Basics Prelude Therapeutics Inc. IPO Date: September 25, 2020 Sector: Healthcare Industry: Biotech Market Cap: $91.78M Activated in VL: True Average Daily Range Avg Daily Range: $0.56 | 4.51% Avg Daily Range (30 D): $0.17 | 11.19% Avg Daily Range (90 D): $0.10 | 7.58% Institutional Daily Volume Avg Daily Volume: .21M Avg Daily Volume (30 D): 1.87M Avg Daily Volume (90 D): .75M Trade Size Avg Trade Size (Sh.): 112 Avg Trade Size (Sh.) (30 D): 158 Avg Trade Size (Sh.) (90 D): 162 Institutional Trades Total Inst.Trades: 334 Avg Inst. Trade: $1.97M Avg Inst. Trade (30 D): $.55M Avg Inst. Trade (90 D): $.55M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.35M Avg Closing Trade (30 D): $.55M Avg Closing Trade (90 D): $.55M Avg Closing Volume: 88.73K     News Dec 6, 2025 @ 4:00 PM Prelude Therapeutics Presents Data at the 2025 ASH... Source: Prelude Therapeutics Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc. May 9, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Citizens JM... Source: Prelude Therapeutics, Inc. Financials   TTM Q3 2025 Q2 2025 Basic EPS $-1.47 $-.26 $-.41 Diluted EPS $-1.47 $-.26 $-.41 Revenue $ 10.5M $ 6.5M $ M Gross Profit $ $ $ Net Income / Loss $ -111.77M $ -19.73M $ -31.23M Operating Income / Loss $ -121.05M $ -20.42M $ -32.19M Cost of Revenue $ $ $ Net Cash Flow $ 35.59M $ 20.97M $ -14.52M PE Ratio